Victorian aged care residents could be included in the next stage of testing for a potential COVID-19 vaccine that has shown positive results during phase one human trials in Adelaide.
- A potential COVID-19 vaccine developed in Adelaide has been shown to be safe and to induce antibodies
- The next stage of trials will include elderly patients in aged care homes
- Victorian aged care homes have been the site of multiple devastating outbreaks
The vaccine candidate, COVAX-19, was developed by Adelaide-based company Vaxine, which has laboratories at Flinders University.
Volunteers between the ages of 18 and 65 in Adelaide have been injected with two doses of either COVAX-19 or a placebo in the phase one trial.
One of the volunteers for the phase one Adelaide trial was SA Best MP Frank Pangallo.
“I feel great — I had my second dose of the vaccine today and no side-effects for me,” Mr Pangallo said on Friday.
“I’m really buoyed by the positive results.”
Lead researcher Professor Nikolai Petrovsky said the vaccine candidate had been shown to be safe and to induce antibodies that attack the coronavirus that causes COVID-19.
“We’ve had no major side-effects in any of the subjects,” said Professor Petrovsky.
He said the vaccine had also shown positive results in trials on animals in the United States in protecting them from COVID-19 infection.
If the vaccine candidate passes subsequent trials, it could be ready by year’s end, he said.
“We can now test the vaccine in nursing home patients and show that it’s effective in inducing the right type of immune responses and hopefully, ultimately, show that it’s effective in preventing them getting infected,” Professor Petrovsky said.
“Based on the safety of the vaccine in that [phase one] group, we’re now actually going into the elderly, which is very relevant given the problems we’re seeing in Victoria.”
Vaccine trials coming to aged care homes
The developers of the vaccine are offering their trial to Victorian aged care facilities, where COVID-19 has taken a devastating toll, among other facilities.
“Under our existing approval for our trials, there’s no reason those trials can’t be extended to Victoria,” Professor Petrovsky said.
“We would just need to identify sites in Victoria that wanted to be part of the trial.”
Those who have recovered from COVID-19 are also candidates for the phase two trial — which will also aim to test whether the drug might help prevent reinfection.
If the vaccine candidate also passes phase two, the final phase would involve testing on a large population with a high incidence of COVID-19 transmission overseas.
From there, Professor Petrovsky said, it would require approval from the Therapeutic Goods Administration before becoming available for distribution in Australia.